Rigel Pharmaceuticals Shares Rose Even As Profit Fell

If you only saw Rigel Pharmaceuticals’ latest quarterly results, with revenue and net income both lower than a year earlier and net margin compressed from 58.6% to 22.0%, you might assume shareholders had a rough ride. Investors who held Rigel Pharmaceuticals over the past year are up 66.2%, including dividends. If you were weighing an investment on 22 October 2025, what did the mix of pipeline promise and earnings quality really signal about taking that risk? Rigel Pharmaceuticals is not the...